CDK

  • Compare CDK Inhibitors
  • Research Area

CDK Inhibitors (24)

water-soluble

Cat.No. Product Name Information Product Citations Customer Reviews
S1116 Palbociclib (PD-0332991) HCl PD0332991 is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 2/3.
  • Proc Natl Acad Sci U S A, 2011, 108(20):8414-9
  • Int J Cancer, 2013, 133(10):2341-50
  • Pigment Cell Melanoma Res, 2012, 26(2):236-46
S2768 Dinaciclib (SCH727965) Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.
  • ACS Chem Biol, 2013, 8(11):2360-5
S1153 Roscovitine (Seliciclib,CYC202) Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM. It shows little effect on CDK4/6. Phase 2.
  • Circ Res, 2012, 111(2):201-11
  • Proc Natl Acad Sci U S A, 2011, 108(20):8414-9
  • J Neurosci, 2012, 32(32):11050-66
S2679 Flavopiridol HCl Flavopiridol competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.
  • Int J Cancer, 2013, 133(10):2341-50
  • Mol Cancer Ther, 2011, 10(9):1624-34
  • Mol Cancer Ther, 2012, 11(11):2321-30
S2621 AZD5438 AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM. It is less potent to CDK5/6 and also inhibits GSK3β. Phase 1.
  • Neoplasia, 2013, 15(8):939-51
S7047 BAY 1000394 BAY 1000394 is an orally bioavailable pan-CDK inhibitor for CDK1/2/3/4/7/9 with IC50 of 5-25 nM. It also potently inhibits Aurora A, Clk2, ARK5, FGFR1, Flt3, and JAK2/3. Phase 1/2.
S7114 NU6027 NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.
S8058 P276-00 p276-00 is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively.
S7158 LY2835219 LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively.
S7320 TG003 TG003 is a potent and ATP-competitive Cdc2-like kinase (Clk) inhibitor with IC50 of 20 nM, 200 nM, and 15 nM for Clk1, Clk2, and Clk4, respectively. No inhibitory effect on Clk3, SRPK1, SRPK2, or PKC.
S7440 LEE011-2 LEE011 is an orally available, and highly specific CDK4/6 inhibitor.
S2735 MK-8776 (SCH 900776) SCH 900776 is a selective Chk1 inhibitor with IC50 of 3 nM. It shows 500-fold selectivity against Chk2. Phase 2.
S1145 SNS-032 (BMS-387032) SNS-032 has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.
  • Proc Natl Acad Sci U S A, 2013, 110(33):13588-93
  • Mol Cancer Ther, 2011, 10(9):1624-34
  • Translational Oncology, 2013, 10.1593/tlo.13544
S1230 Flavopiridol (Alvocidib) Flavopiridol (Alvocidib) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1, 2, 4, 6 versusCDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.
  • Leukemia, 2014, 28(3):629-41
  • Proc Natl Acad Sci U S A, 2011, 108(20):8414-9
  • Int J Cancer, 2013, 133(10):2341-50
S1249 JNJ-7706621 JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6. It also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1.
S1487 PHA-793887 PHA-793887 is a novel and potent inhibitor of CDK2, CDK5 and CDK7 with IC50 of 8 nM, 5 nM and 10 nM. It is greater than 6-fold more selective for CDK2, 5, and 7 than CDK1, 4, and 9. Phase 1.
  • Anticancer Agents Med Chem, 2011, 11(5):418-26
S1524 AT7519 AT7519 is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM. It is less potent to CDK3 and little active to CDK7. Phase 1.
  • J Biol Chem, 2012, 287(52):43639-50
  • PLoS One, 2011, 6(9):e25683
  • Nat Biotechnol, 2013, 32(1):92-6
S1572 BS-181 HCl BS-181 is a highly selective CDK7 inhibitor with IC50 of 21 nM. It is more than 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.
  • Arthritis Rheumatol, 2014, 10.1002/art.38378
S2670 A-674563 A-674563 is an Akt1 inhibitor with Ki of 11 nM, modest potent to PKA and >30-fold selective for Akt1 over PKC.
S2688 R547 R547 is a potent ATP-competitive inhibitor of CDK1/2/4 with Ki of 2 nM/3 nM/1 nM. It is less potent to CDK7 and GSK3α/β, while inactive to other kinases.
S2742 PHA-767491 PHA-767491 is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.It displays ~20-fold selectivity against CDK1/2 and GSK3-β, 50-fold selectivity against MK2 and CDK5, 100-fold selectivity against PLK1 and CHK2.
S2751 Milciclib (PHA-848125) PHA-848125 is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. Phase 2.
S2014 BMS-265246 BMS-265246 is a potent and selective CDK1/2 inhibitor with IC50 of 6 nM/9 nM. It is 25-fold more selective for CDK1/2 than CDK4.
S1579 Palbociclib (PD0332991) Isethionate Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 2/3.
  • Proc Natl Acad Sci U S A, 2013, 110(10):4015-20
  • Neoplasia, 2013, 15(8):939-51
  • Cell Cycle, 2013, 12(18):3063-9